HIV drug combo have no benefit for COVID-19 patients in UK trial

Topics Coronavirus | HIV | healthcare

A combination of antiviral drugs commonly used to treat HIV showed no beneficial effects in patients hospitalised with COVID-19 in a large-scale randomised trial, scientists in the UK have found.

The findings "convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied," the scientists running the RECOVERY trial at the University of Oxford said in a statement on Monday.

In March, the RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV.

Over 11,800 patients have been enrolled from 176 NHS hospitals in the UK for the trial.

On Monday, the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19.

A total of 1,596 patients were randomised to lopinavir-ritonavir and compared with 3,376 patients randomised to usual care alone, the statement said.

Of these patients, four per cent required invasive mechanical ventilation when they entered the trial, 70 per cent required oxygen alone, and 26 per cent did not require any respiratory intervention, it said.

There was no significant difference in mortality for lopinavir-ritonavir compared to usual care, and the results were consistent in different subgroups of patients, the scientists said.

There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay, they said.

"These preliminary results show that for patients hospitalised with COVID-19 and not on a ventilator, lopinavir-ritonavir is not an effective treatment. In 100 days, the RECOVERY trial has provided results enabling change in global practice three times," said Peter Horby, Professor at the University of Oxford, and chief investigator for the trial.

The researchers said they were unable to study a large number of patients on invasive mechanical ventilation because of difficulty administering the drug to patients on ventilators.

As such, they cannot make conclusions about the effectiveness in mechanically ventilated patients, the researchers said, adding full results will be made available as soon as possible.

"These are clear results and once again emphasise the value of large randomised clinical trials in differentiating drugs we hope work from treatments we know do work," said Martin Landray, Professor of Medicine and Epidemiology at the University of Oxford.

"In many countries, current guidelines recommend lopinavir-ritonavir as a treatment for COVID-19," said Landray, Deputy Chief Investigator of the trial.

The results from this trial, together with those from other large randomised trials, should inform revisions to those guidelines and changes to the way individual patients are treated, the researchers said.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel